Upstream Bio, a Waltham, Mass.-based biotech company focused on inflammation, raised $200 million in Series A financing.
The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd.
The company plans to use the funds for UPB-101, a monoclonal antibody in clinical-stage development that targets the TSLP receptor and to build a pipeline of assets that will address immune-mediated disorders.
Following the conclusion of preclinical and clinical trials, Upstream Bio bought UPB101 from Astellas. Upstream Bio has chosen asthma as its first indication for UPB101. It plans to expand the research into other diseases that are TSLP-mediated. It is possible to inhibit TSLP signaling. TSLP signaling is activated by allergens, viruses and other triggers. It is at the top end of the inflammatory cascade, and a key driver for the inflammatory response in major allergic or inflammatory diseases like asthma. TSLP signals occur upstream from other valid targets like IL-4, IL-5 and IL-13.